Nine of our senior team made the trip to Copenhagen to represent Mtech Access at ISPOR Europe this November. The conference brought together leading experts from across Health Economics and Outcomes Research to share ideas and explore the latest trends. At our booth, we were delighted to meet with a number of current and past clients. We also had some interesting conversations with some great new contacts.

A big highlight for us was the poster presentations. We entered five posters under the Mtech Access brand and were thrilled when we received a top 10% rosette for our poster: ‘A systematic review assessing the long-term effects of maintaining RAASi treatment in patients with chronic kidney disease ‘.

Scroll down to find out more about each of our five posters and what inspired us to present these topics at ISPOR.

We submitted the following five posters:

Poster 1: Delay in diagnosis of primary lymphoedema and its impact on quality of life: a systematic review

Mtech Access Consultant, Catherine Mitchell, conducted this research in collaboration with her friend Dr Catherine O’Leary (a portfolio GP), whose daughter and husband both have primary lymphoedema.

Lymphoedema is a chronic condition that, if left untreated, can severely impact on patients’ quality of life. With no standardised education on primary lymphoedema offered to healthcare professionals in England, the condition is often under or misdiagnosed. Early diagnosis and treatment reduces its psychological and social impact and prevents disease progression and complications.

The objectives and conclusions of this research examining the time from initial symptoms to diagnosis are summarised here on the ISPOR presentation database.

Prior to ISPOR, Dr Catherine O’Leary was invited to present the preliminary results of the research at the British Lymphology Society, where she won “best overall oral presentation”.

Contact Catherine on catherine.mitchell@mtechaccess.co.uk if you would like to find out more about this research or to request a copy of our poster.

Poster 2: Animal assisted therapy (AAT) in depression and anxiety: a systematic review

Ezinne Byrne, an analyst in our systematic review team, was inspired by her love of animals to conduct this systematic review into how AAT can support patients with depression and anxiety.

Interestingly, a wide range of animals were employed as part of the AAT regimen including dogs, cats, and horses, as well as dolphins and farm animals such as cows, pigs, and chickens.

Click here to access a summary of the research on the ISPOR database.

In the weeks prior to ISPOR, some of our systematic review team applied the findings of this review when they brought their dogs into the office for the day (unfortunately we couldn’t accommodate horses or dolphins!)

Contact Ezinne on ezinne.byrne@mtechaccess.co.uk if you would like to find out more about this research or to request a copy of our poster.

Poster 3: A systematic review assessing the long-term effects of maintaining RAASi treatment in patients with chronic kidney disease

This systematic review was conducted in collaboration with our client, AstraZeneca, who chose Mtech Access to support their evidence generation around the long-term effects of maintaining renin–angiotensin–aldosterone system inhibitors (RAASi) treatment in patients with chronic kidney disease (CKD).

The review found that the use of RAASi improved long-term clinical outcomes, including providing a significant reduction in all-cause mortality and cardiovascular events compared with placebo in patients with CKD. RAASi therapy also significantly reduced the risk of disease progression to end stage renal disease and the need for dialysis versus placebo.

The ISPOR presentation database once again holds a summary of the findings.

Our team were thrilled when this poster received a top 10% rosette.

Contact Sarah Batson on sarah.batson@mtechaccess.co.uk if you would like to find out more about this research or to request a copy of our poster.

Poster 4: The long-term effects of maintaining RAASi treatment in patients with heart failure: a systematic review

Our work with AstraZeneca saw us present another systematic review on RAASi treatment, this time on patients with heart failure.

Treatment with renin–angiotensin–aldosterone system inhibitors (RAASi) in patients with heart failure is established clinical practice to reduce the incidence of adverse cardiovascular events, hospitalisations, and mortality. This systematic review looked at the long-term clinical benefits of RAASi treatment, how it affects disease progression, and how discontinuation affects patients’ long-term health.

Once again, this poster was a collaborative effort between our evidence team and the team at AstraZeneca. On the right, Sarah Batson, who leads our statistical analysis capability, is pictured with the poster in the exhibit hall at ISPOR Europe.

See a summary of the findings in the ISPOR database here.

Contact Sarah Batson on sarah.batson@mtechaccess.co.uk if you would like to find out more about this research or to request a copy of our poster.

Poster 5: Updated meta-analysis of the efficacy of adjuvant treatment to levodopa in Parkinson’s disease

Stephen Mitchell (Director-Evidence, Mtech Access) collaborated with Sarah Batson and Neil Branscombe of Branscombe Consulting (Saint Omer, France) to conduct this meta-analysis update.

The meta-analysis explored anti-Parkinson’s disease interventions that can be added to levodopa therapy as adjuvant therapies in order to reduce motor complications when treating Parkinson’s disease.

You can learn more about our approach and findings in the ISPOR presentation database.

This meta-analysis was originally conducted to support a client’s evidence submission as part of their broader market access strategy.

Contact Stephen Mitchell on stephen.mitchell@mtechaccess.co.uk if you would like to find out more about this research or to request a copy of our poster.

ISPOR Europe saw us present five posters under the Mtech Access brand. In addition, one of our clients also presented a poster featuring research conducted by our evidence team as part of a recent project.

Our posters featured independent research on topics close to our team members’ hearts, along with presentations of evidence commissioned by our clients to further their market access strategies.

We are already thinking about our presentations for 2020 and would be delighted to hear from anyone interested in submitting a poster or working with our evidence team.

If you work in market access in pharma, bio-pharma, or medical devices and would like to discuss how our evidence team can support your market access strategy by submitting evidence at conferences like ISPOR, contact Stephen Mitchell on stephen.mitchell@mtechaccess.co.uk.

If you would like to suggest a topic for independent research, or if you are a medical professional or academic who would like to collaborate with our team on research, contact Catherine Mitchell on catherine.mitchell@mtechaccess.co.uk.

Leave a Reply